Casual Blood Glucose Testing Misses ~70 Percent of Gestational Diabetes Cases
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 27, 2024 -- Casual blood glucose (CBG) testing at 24 to 28 gestational weeks misses about 70 percent of women with gestational diabetes mellitus (GDM), according to a study published online Sept. 18 in the Journal of Diabetes Investigation.
Masako Tomimoto, M.D., from the Kobe University Graduate School of Medicine in Japan, and colleagues enrolled 763 pregnant women who underwent the 50-g glucose challenge test (GCT) at 24 to 28 gestational weeks to examine problems in screening for GDM by CBG measurements. The preload blood glucose (0-h BG) on 50-g GCT with CBG was identified, and the relationship between 50-g GCT positivity (1-h BG on 50-g GCT ≥140 mg/dL) and CBG positivity (0-h BG on 50-g GCT ≥100 mg/dL) was examined.
The researchers found that of the 240 women with 50-g GCT positivity who underwent the 75-g oral glucose tolerance test, GDM was diagnosed in 98 (40.8 percent). Overall, 71 (71.7 percent) of the 99 women with GDM had 0-h BG <100 mg/dL on 50-g GCT.
"Although there have been studies showing that the casual blood glucose test is less sensitive than others, no studies have directly compared the results in the same individuals," Tomimoto said in a statement. "Our study confirmed that this screening method, which is widely used in practice, frequently misses the condition it is meant to detect."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-28 06:00
Read more
- Decline Expected in HIV Care Providers in Next Five Years
- Doctors Report First U.S. Cases of Sexually Transmitted Ringworm Rash
- Burger King, Other Fast Food Chains Also Pulling Onions Tied to E. Coli Outbreak
- '10 Americas:' Health Disparities Mean Life Expectancy Varies Across U.S.
- Primary Care Encounter Notes Often Lack Thoroughness
- More Than One-Third Have ED Visit Within 90 Days Before Cancer Diagnosis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions